Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 6/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1893123 | 0.92 | KDM1A (0.47) | KDM1AHTR2AHTR2CHTR2BRCOR1 | |
| SCHEMBL22528221 | 0.89 | KDM1A (0.41) | KDM1AHTR2AHTR2CHTR2BMEN1 | |
| SCHEMBL11638570 | 0.81 | KDM1A (0.44) | KDM1AHTR2AHTR2CHTR2BRCOR1 | |
| SCHEMBL3105747 | 0.80 | KDM1A (0.43) | KDM1AHTR2AHTR2CHTR2BRCOR1 | |
| SCHEMBL3564666 | 0.78 | CCNB2 (0.31) | — | |
| SCHEMBL610893 | 0.77 | TSHR (0.54) | KDM1AHTR2AHTR2CHTR2BRCOR1 | |
| SCHEMBL264648 | 0.77 | KDM1A (0.47) | KDM1AHTR2AHTR2CHTR2BRCOR1 | |
| SCHEMBL29364885 | 0.77 | TSHR (0.54) | KDM1AHTR2AHTR2CHTR2BRCOR1 | |
| SCHEMBL15279432 | 0.77 | HTR2C (0.40) | HTR2CMEN1KMT2AHDAC4ALDH1A1 | |
| SCHEMBL7784351 | 0.77 | TSHR (0.54) | KDM1AHTR2AHTR2CHTR2BRCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082582-A1 | Process For Preparing [2-(2,3- Dihydrobenzofuran - Or Benzofuran-7-Yloxy)Ethyl]-(3 -Cyclopent-1-Ylbenzyl)Amine Derivatives and Synthesis Intermediate | PIERRE FABRE MEDICAMENT (FR) | 2009-03-26 | — | — | US | claimed |
| EP-1996570-A1 | PROCESS FOR PREPARING [2-(2,3-DIHYDROBENZOFURAN- OR BENZOFURAN-7-YLOXY)ETHYL]-(3-CYCLOPENT-1-YLBENZYL)AMINE DERIVATIVES AND SYNTHESIS INTERMEDIATE | Pierre Fabre Médicament S.A. (FR) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104872-A1 | PROCESS FOR PREPARING [2-(2,3-DIHYDROBENZOFURAN- OR BENZOFURAN-7-YLOXY)ETHYL]-(3-CYCLOPENT-1-YLBENZYL)AMINE DERIVATIVES AND SYNTHESIS INTERMEDIATE | PIERRE FABRE MEDICAMENT (FR) | 2007-09-20 | — | — | WO | claimed |
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | ORSOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4570313-A2 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-06-18 | — | — | EP | disclosed |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2025-06-12 | — | — | US | disclosed |
| CN-120092003-A | CDK protein degrading agents, pharmaceutical compositions and therapeutic uses | 拜欧斯瑞克斯公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-3615515-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059808-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023220640-A1 | CDK PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-4755520-A | Spartein compounds, their preparation and use | KALI-CHEMIE PHARMA GMBH (DE) | 1988-07-05 | — | — | US | disclosed |
| EP-0257309-A2 | Process for the preparation of ethynylbenzaldehydes | National Starch and Chemical Investment Holding Corporation (US) | 1988-03-02 | — | — | EP | disclosed |
| EP-0249950-A1 | Aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-12-23 | — | — | EP | disclosed |
| EP-0235000-A1 | Iodine-labelled pyrethrinoids, process for their preparation and their use in radioimmuno-assays | ROUSSEL-UCLAF (FR) | 1987-09-02 | — | — | EP | disclosed |
| EP-0211561-A1 | Insecticidal ethers | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-02-25 | — | — | EP | disclosed |
| CN-86105891-A | Desinsection ether | — | 1987-02-25 | — | — | CN | disclosed |
| EP-0206155-A1 | Aromatic compounds, their preparation and use | Kali-Chemie Pharma GmbH (DE) | 1986-12-30 | — | — | EP | disclosed |
| US-4594355-A | Phenyl ring with a 2,2-dimethylcyclopropanecarboxylic group on ring and a dihalovinyl group in position 3 | NATIONAL RESEARCH DEVELOPMENT CORP. (GB) | 1986-06-10 | — | — | US | disclosed |
| EP-0085959-A2 | Aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078105-A1 | Novel Aminocarboxymuconate Semialdehyde Decarboxylase Inhibitors | CPT1B, CBR1, MUSK | KDM1A 2738/4885HTR2A 3148/4885HTR2C 3076/4885 |
| US-20250188110-A1 | SPECIFIC SMALL MOLECULE INHIBITORS THAT BLOCK KMT9 METHYLTRANSFERASE ACTIVITY AND FUNCTION | KMT5A, KMT5B, KMT5C | KDM1A 25/4885HTR2A 4683/4885HTR2C 4689/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | KDM1A 1404/4885HTR2A 3357/4885HTR2C 4327/4885 |
| US-20090082582-A1 | Process For Preparing [2-(2,3- Dihydrobenzofuran - Or Benzofuran-7-Yloxy)Ethyl]-(3 -Cyclopent-1-Ylbenzyl)Amine Derivatives and Synthesis Intermediate | TAC3, NCAPD3, PAH | KDM1A 2576/4885HTR2A 1437/4885HTR2C 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.